CellCentric
UK biotech developing inobrodib for multiple myeloma; Europe's largest private biotech round in 2026.
Last refreshed: 13 May 2026 · Appears in 1 active topic
How did a UK biotech raise Europe's biggest 2026 private round with zero public money?
Timeline for CellCentric
Closed oversubscribed $220m Series D to fund Phase 2 DOMMINO-1 trials for inobrodib in multiple myeloma
UK Startups and Innovation: CellCentric raises Europe's largest 2026 biotech roundMentioned in: Cytospire's £61m oncology Series A oversubscribed
UK Startups and Innovation- What drug is CellCentric developing for multiple myeloma?
- CellCentric is developing inobrodib, an oral p300/CBP inhibitor for relapsed and refractory multiple myeloma, currently in Phase 2 DOMMINO-1 trials in the UK and US.Source: CellCentric
- How much did CellCentric raise in 2026?
- CellCentric raised $220m in a Series D on 5 May 2026, led by Venrock Healthcare Capital Partners, reported as Europe's largest private biotech financing of 2026.Source: BioSpace / Lowdown
- What is a p300 CBP inhibitor and how does it treat cancer?
- A p300/CBP inhibitor blocks epigenetic regulators that cancer cells exploit to silence anti-tumour genes; in multiple myeloma, this approach aims to restore tumour-suppressor activity without the toxicity of chemotherapy.
- When will CellCentric start its Phase 3 myeloma trial?
- CellCentric plans to launch the Phase 3 DOMMINO-2 trial in H2 2026 following positive Phase 2 DOMMINO-1 data.Source: Lowdown
Background
CellCentric raised $220m in a Series D on 5 May 2026, reported by BioSpace as the largest private biotech financing in Europe in 2026. The round was led by Venrock Healthcare Capital Partners with Fidelity Management and Research, Sofinnova Partners, HBM Healthcare, RA Capital, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge initiative. No UK public investor participated, making it the largest UK biotech round of 2026 funded entirely by private and transatlantic capital.
The capital funds the Phase 2 DOMMINO-1 trial of inobrodib, CellCentric's oral p300/CBP inhibitor for relapsed and refractory multiple myeloma, running across the UK and US. Phase 3 DOMMINO-2 is planned for H2 2026. inobrodib targets the p300 and CBP epigenetic regulators, which multiple myeloma cells exploit to suppress anti-tumour gene expression; oral administration and an epigenetic mechanism make it a differentiated candidate in a market where novel combinations are sought for patients whose disease has progressed on standard regimens.
The absence of BBB or SAIU participation in Europe's largest 2026 biotech round is notable: it shows UK-headquartered companies can access US-scale capital without government anchoring, while also prompting questions about whether sovereign investment capacity is being deployed selectively.